Immunocore Holdings (IMCR) Non-Current Deffered Revenue (2019 - 2026)

Immunocore Holdings (IMCR) has reported Non-Current Deffered Revenue for 8 consecutive years, with $4.6 million the latest figure, recorded in Q1 2026.

• Quarterly Non-Current Deffered Revenue fell 17.64% year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (down 17.64% YoY) and the FY2025 annual result came in at $4.9 million, down 10.6% from the prior year.
• Non-Current Deffered Revenue eased to $4.6 million in Q1 2026 per IMCR's latest filing, from $4.9 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for IMCR reached as high as $5.8 million in Q3 2024 and fell as low as $4.6 million in Q1 2026.
• A 5-year average of $5.3 million and a median of $5.4 million in 2023 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue plunged 41.19% — and 2023, when it grew 8.56%.
• Year by year, Non-Current Deffered Revenue stood at $5.1 million in 2022, then grew by 8.56% to $5.5 million in 2023, then declined by 1.47% to $5.4 million in 2024, then declined by 10.6% to $4.9 million in 2025, then decreased by 4.86% to $4.6 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $4.6 million, $4.9 million, and $5.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.